Erratum to: Different CSF β -amyloid processing in Alzheimer's and Creutzfeldt–Jakob disease

Brit Mollenhauer · Hermann Esselmann · Sigrun Roeber ·
Walter J. Schulz-Schaeffer · Claudia Trenkwalder · Mirko Bibl ·
Petra Steinacker · Hans A. Kretzschmar · Jens Wiltfang · Markus Otto

Published online: 15 June 2011
© Springer-Verlag 2011

Erratum to: J Neural Transm (2011) 118:691–697
DOI 10.1007/s00702-010-0543-z

Unfortunately, the online published article has errors in Table 2. The units must be ng/mg instead of ng/ml in the entire column of Brain.

The correct table is given in the following page.

The online version of the original article can be found under doi:[10.1007/s00702-010-0543-z](https://doi.org/10.1007/s00702-010-0543-z).

B. Mollenhauer (✉) · C. Trenkwalder
Paracelsus-Elena Klinik, Kassel and Georg-August University,
Göttingen, Germany
e-mail: brit.mollenhauer@pk-mx.de

H. Esselmann · J. Wiltfang
Department of Psychiatry, Rheinische Kliniken Essen,
University of Duisburg-Essen, Essen, Germany

S. Roeber · H. A. Kretzschmar
Department of Neuropathology, Ludwig Maximilians
University, Munich, Germany

W. J. Schulz-Schaeffer
Department of Neuropathology, University Medical Center,
Göttingen, Germany

M. Bibl
Kliniken Essen Mitte, Department of Psychiatry,
Psychotherapy and addiction medicine, University
of Duisburg-Essen, Henricistrasse 92, 45136 Essen, Germany

P. Steinacker · M. Otto
Department of Neurology, University of Ulm, Ulm, Germany

Table 2 Quantitative analysis of the mean A β peptide species 1–42, 1–40 and 1–38 as well as A β total in the intra vitam CSF by A β SDS-PAGE/immunoblot (detection antibody, mAb 1E8) and the correspondent detergent-soluble fraction of immunoprecipitation from brain homogenates (mAb 1E8) of patients with Alzheimer's disease (AD), Creutzfeldt–Jakob disease (CJD) and from controls (CGc and CGp) (mean $\pm$ standard deviation)

Disease	AD	CJD										Comparison group (CG)					
												CGc		CGp			
		B (n = 4)		C (n = 10)		0 (n = 5)		A (n = 2)		B (n = 2)		(n = 10)		0 (n = 6)			
CERAD		A (n = 1)	Brain ng/ml	CSF ng/ml	Brain ng/mg	CSF ng/ml	Brain ng/mg	CSF ng/ml	Brain ng/mg	CSF ng/ml	Brain ng/mg	CSF ng/ml	Brain ng/mg	CSF ng/ml	Brain ng/mg	Brain ng/mg	
		A/1-42	0.27	12.730	0.31 ± 0.27	16.234 ± 14.762	0.25 ± 0.18	24.827 ± 8.678	0.38 ± 0.26	0.010 ± 0.007	0.38 ± 0.19	22.096 ± 30.397	0.23 ± 0.23	2.056 ± 2.102	1.66 ± 0.4	0.05 ± 0.013	4.088
		A/1-40	2.73	0.144	4.371 ± 1.80	20.482 ± 21.859	3.54 ± 2.15	13.529 ± 22.078	3.24 ± 2.03	0.016 ± 0.004	3.4 ± 1.7	8.744 ± 12.347	2.86 ± 3.19	0.061 ± 0.058	9.12 ± 2.1	0.016 ± 0.007	0.141
		A/1-38	0.78	0.098	1.24 ± 0.90	3.929 ± 5.113	0.62 ± 0.27	6.725 ± 11.193	0.65 ± 0.39	0.005 ± 0.004	0.71 ± 0.35	1.142 ± 1.502	0.57 ± 0.57	0.052 ± 0.037	2.04 ± 0.48	0.006 ± 0.006	0.352
		Aβ total	4.8	15.377	7.55 ± 3.70	46.193 ± 42.224	5.33 ± 2.97	61.436 ± 51.914	5.10 ± 3.25	0.031 ± 0.009	5.37 ± 2.61	36.310 ± 50.339	4.32 ± 4.61	2.723 ± 2.885	15.19 ± 3.36	0.088 ± 0.168	5.581

In the brains the occurrence of neuritic plaque pathology was semi quantitatively determined according to the classification (age-related plaque scores 0, A, B, C) of The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (Mira et al. 1991)